Skip to content

Author

Yubin Luo

We have 2 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

ALKBH5 inhibitors for cancer therapy: molecular docking, challenges and future prospects

N 6 -Methyladenosine (m 6 A), the most abundant internal modification of eukaryotic mRNA, is dynamically reversed by the Fe II /α-ketoglutarate-dependent dioxygenase ALKBH5, a key m 6 A “eraser” that regulates target mRNA fate through demethylation. ALKBH5 is aberrantly overexpressed in acute myeloid leukemia...

Chen Deng, Hai Xu, Jian Pu et al. · 0 citations
Jul 2026

Repurposing simeprevir uncovers a druggable KPNB1-p65-BCL2 survival axis in cancer.

This study elucidates a therapeutically targetable KPNB1-p65-Bcl-2 survival axis in multiple cancers and establishes a foundation for developing next-generation KPNB1 inhibitors.

Cong Li, Qiaohua Yan, Muhammad Muddasar Saeed et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.